JP2023539194A5 - - Google Patents

Info

Publication number
JP2023539194A5
JP2023539194A5 JP2023513110A JP2023513110A JP2023539194A5 JP 2023539194 A5 JP2023539194 A5 JP 2023539194A5 JP 2023513110 A JP2023513110 A JP 2023513110A JP 2023513110 A JP2023513110 A JP 2023513110A JP 2023539194 A5 JP2023539194 A5 JP 2023539194A5
Authority
JP
Japan
Prior art keywords
alkyl
compound
tautomer
pharmaceutically acceptable
optionally substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2023513110A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023539194A (ja
JP7743504B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/047754 external-priority patent/WO2022047031A1/en
Publication of JP2023539194A publication Critical patent/JP2023539194A/ja
Publication of JP2023539194A5 publication Critical patent/JP2023539194A5/ja
Priority to JP2025150349A priority Critical patent/JP2025183328A/ja
Application granted granted Critical
Publication of JP7743504B2 publication Critical patent/JP7743504B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2023513110A 2020-08-26 2021-08-26 Apol1の阻害剤およびこれを使用する方法 Active JP7743504B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025150349A JP2025183328A (ja) 2020-08-26 2025-09-10 Apol1の阻害剤およびこれを使用する方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063070705P 2020-08-26 2020-08-26
US63/070,705 2020-08-26
PCT/US2021/047754 WO2022047031A1 (en) 2020-08-26 2021-08-26 Inhibitors of apol1 and methods of using same

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025150349A Division JP2025183328A (ja) 2020-08-26 2025-09-10 Apol1の阻害剤およびこれを使用する方法

Publications (3)

Publication Number Publication Date
JP2023539194A JP2023539194A (ja) 2023-09-13
JP2023539194A5 true JP2023539194A5 (https=) 2024-08-30
JP7743504B2 JP7743504B2 (ja) 2025-09-24

Family

ID=77822053

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2023513110A Active JP7743504B2 (ja) 2020-08-26 2021-08-26 Apol1の阻害剤およびこれを使用する方法
JP2025150349A Pending JP2025183328A (ja) 2020-08-26 2025-09-10 Apol1の阻害剤およびこれを使用する方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025150349A Pending JP2025183328A (ja) 2020-08-26 2025-09-10 Apol1の阻害剤およびこれを使用する方法

Country Status (21)

Country Link
US (2) US11866446B2 (https=)
EP (1) EP4204423A1 (https=)
JP (2) JP7743504B2 (https=)
KR (1) KR20230057386A (https=)
CN (1) CN116547287B (https=)
AR (1) AR123355A1 (https=)
AU (1) AU2021333776A1 (https=)
BR (1) BR112023003423A2 (https=)
CA (1) CA3190609A1 (https=)
CL (1) CL2023000536A1 (https=)
CO (1) CO2023003026A2 (https=)
CR (1) CR20230132A (https=)
DO (1) DOP2023000042A (https=)
EC (1) ECSP23020167A (https=)
IL (2) IL318169A (https=)
JO (1) JOP20230035A1 (https=)
MX (1) MX2023002269A (https=)
PE (1) PE20231106A1 (https=)
SA (1) SA523442662B1 (https=)
UY (1) UY39395A (https=)
WO (1) WO2022047031A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11618746B2 (en) 2018-12-17 2023-04-04 Vertex Pharmaceuticals Incorporated Inhibitors of APOL1 and methods of using same
WO2021154997A1 (en) 2020-01-29 2021-08-05 Vertex Pharmaceuticals Incorporated Inhibitors of apol1 and methods of using same
IL296035A (en) 2020-03-06 2022-10-01 Vertex Pharma Methods of treating apol-1 dependent focal segmental glomerulosclerosis
CN115867543A (zh) 2020-06-12 2023-03-28 弗特克斯药品有限公司 Apol1抑制剂的固体形式及其使用方法
CA3185604A1 (en) 2020-06-12 2021-12-16 Vertex Pharmaceuticals Incorporated Inhibitors of apol1 and use of the same
CN116547287B (zh) * 2020-08-26 2025-09-26 弗特克斯药品有限公司 Apol1的抑制剂及其使用方法
US20230119114A1 (en) * 2021-08-26 2023-04-20 Vertex Pharmaceuticals Incorporated Solid forms of apol1 inhibitors and methods of using same
US12612379B2 (en) 2021-11-30 2026-04-28 Vertex Pharmaceuticals Incorporated Inhibitors of APOL1 and methods of using same
MX2024008868A (es) 2022-01-18 2024-09-23 Maze Therapeutics Inc Inhibidores de la apolipoproteína l1 (apol1) y métodos de uso.
CA3251050A1 (en) * 2022-02-08 2023-08-17 Vertex Pharmaceuticals Incorporated 2-METHYL-4',5'-DIHYDROSPIRO[PIPERIDINE-4,7'-THIENO[2,3-C]PYRAN] DERIVATIVES USED AS APOL1 INHIBITORS AND THEIR METHODS OF USE
WO2024249252A1 (en) * 2023-05-26 2024-12-05 Maze Therapeutics, Inc. Methods of using apol1 inhibitors
AU2024343017A1 (en) 2023-09-11 2026-03-19 Vertex Pharmaceuticals Incorporated Process for preparing (2s,4s,4's,6s)-2-methyl-6-(1-methyl-1h-1,2,3-triazol-4-yl)-2',-(trieluoromethyl)-4',5'-dihydrospiro[piperidine-4,7'-thieno [2,3-c] pyran] -4'-ol

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4039676A (en) 1975-06-23 1977-08-02 Ciba-Geigy Corporation 2-piperidinoalkyl-1,4-benzodioxans
US6518423B1 (en) 1996-08-09 2003-02-11 Eisai Co., Ltd. Benzopiperidine derivatives
AU7514700A (en) 1999-09-07 2001-04-10 Syngenta Participations Ag Cyanopiperidines
FR2801585B1 (fr) 1999-11-25 2002-02-15 Fournier Ind & Sante Nouveaux antagonistes des recepteurs de l'ii-8
AU2002211828A1 (en) 2000-10-02 2002-04-15 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
FR2824827B1 (fr) 2001-05-17 2004-02-13 Fournier Lab Sa Nouveaux derives de 5-phenyl-1h-indole antagoniste des recepteurs de l'interleukine-8
FR2824826B1 (fr) 2001-05-17 2003-11-07 Fournier Lab Sa Nouveaux derives de 5-cyano-1h-indole antagonistes des recepteurs de l'interleukine-8
US20030119060A1 (en) 2001-08-10 2003-06-26 Desrosiers Peter J. Apparatuses and methods for creating and testing pre-formulations and systems for same
WO2003104180A1 (en) 2002-06-05 2003-12-18 Natco Pharma Limited Process for the preparation of 4-(4-fluorobenzoyl) butyric acid
JP2007504221A (ja) 2003-09-03 2007-03-01 ガラパゴス・エヌブイ 新規な4−ピペリジンカルボキシアミドおよび5ht2a受容体関連障害に対する薬剤の製造のためのその使用
BRPI0507657A (pt) 2004-03-03 2007-07-10 Lilly Co Eli composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, método para tratar um distúrbio, e, uso de um composto ou um sal farmaceuticamente aceitável do mesmo
AR048523A1 (es) 2004-04-07 2006-05-03 Kalypsys Inc Compuestos con estructura de aril sulfonamida y sulfonilo como moduladores de ppar y metodos para tratar trastornos metabolicos
US8222288B2 (en) 2006-08-30 2012-07-17 The Regents Of The University Of Michigan Small molecule inhibitors of MDM2 and the uses thereof
JP5406722B2 (ja) 2006-10-16 2014-02-05 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング ブラジキニン1受容体モジュレータとしての置換されたスルホンアミド誘導体
BRPI0721138A2 (pt) 2006-12-22 2014-04-01 Hoffmann La Roche Derivados de espiro-piperidina
PT2118074E (pt) 2007-02-01 2014-03-20 Resverlogix Corp Compostos para a prevenção e tratamento de doenças cardiovasculares
EP2020414A1 (en) 2007-06-20 2009-02-04 Laboratorios del Dr. Esteve S.A. spiro[piperidine-4,4'-thieno[3,2-c]pyran] derivatives and related compounds as inhibitors of the sigma receptor for the treatment of psychosis
DK2178870T3 (en) 2007-08-17 2018-10-22 Lg Chemical Ltd INDOLE AND INDAZOLIC COMPOUNDS AS AN INHIBITOR OF CELLULAR NECROSE
CN105254557A (zh) 2009-05-29 2016-01-20 拉夸里亚创药株式会社 作为钙或钠通道阻滞剂的芳基取代羧酰胺衍生物
UA107943C2 (xx) 2009-11-16 2015-03-10 Lilly Co Eli Сполуки спіропіперидину як антагоністи рецептора orl-1
AU2010319400B2 (en) 2009-11-16 2013-12-19 Eli Lilly And Company Spiropiperidine compounds as ORL-1 receptor antagonists
WO2012025155A1 (en) 2010-08-26 2012-03-01 Novartis Ag Hydroxamate-based inhibitors of deacetylases
BR102012024778A2 (pt) 2012-09-28 2014-08-19 Cristalia Prod Quimicos Farm Compostos heteroaromáticos; processo para preparar os compostos, composições farmacêuticas, usos e método de tratamento para as dores aguda e crônica
US10130632B2 (en) 2012-11-27 2018-11-20 Beth Israel Deaconess Medical Center, Inc. Methods for treating renal disease
EP3049405A4 (en) 2013-09-26 2017-03-08 Pharmakea Inc. Autotaxin inhibitor compounds
EP3186225A4 (en) 2014-08-27 2018-02-28 The Governing Council of the University of Toronto Cannabinoid type 1 receptor modulators
US10654838B2 (en) 2014-10-08 2020-05-19 Institut National De La Sante Et De La Recherche Medicale (Inserm) Aminopyridine compounds useful as inhibitors of protein prenylation
JP2017535545A (ja) 2014-11-21 2017-11-30 ラボラトリオス・デル・デエレ・エステベ・エセ・ア 疼痛に対する多様な活性を有するスピロ−イソキノリン−1,4’−ピペリジン化合物
HUE053705T2 (hu) 2015-08-27 2021-07-28 Pfizer Biciklusos kondenzált heteroaril- vagy aril- vegyületek IRAK4 modulátorokként
WO2017137334A1 (en) 2016-02-08 2017-08-17 F. Hoffmann-La Roche Ag Spiroindolinones as ddr1 inhibitors
MX390141B (es) 2017-02-16 2025-03-20 Sunovion Pharmaceuticals Inc Metodos para tratar esquizofrenia
UY37956A (es) * 2017-11-02 2019-05-31 Abbvie Inc Moduladores de la vía de estrés integrada
EP3787669A4 (en) 2018-04-30 2022-03-30 The Trustees of Indiana University COMPOUNDS FOR MODULATION OF LEVELS OF DDAH AND ADMA AND METHODS OF USE THEM TO TREAT DISEASES
US11618746B2 (en) * 2018-12-17 2023-04-04 Vertex Pharmaceuticals Incorporated Inhibitors of APOL1 and methods of using same
US20220144838A1 (en) 2019-03-13 2022-05-12 Nanjing Immunophage Biotech Co., Ltd. Compounds as Inhibitors of Macrophage Migration Inhibitory Factor
CA3156359A1 (en) 2019-11-08 2021-05-14 Adrian Liam Gill Bicyclic heteroaryl compounds and uses thereof
TW202136219A (zh) 2019-12-19 2021-10-01 美商卡司馬療法公司 Trpml調節劑
WO2021154997A1 (en) 2020-01-29 2021-08-05 Vertex Pharmaceuticals Incorporated Inhibitors of apol1 and methods of using same
US20210246121A1 (en) 2020-02-04 2021-08-12 Vertex Pharmaceuticals Incorporated Solid forms of apol1 inhibitor and methods of using same
IL296035A (en) 2020-03-06 2022-10-01 Vertex Pharma Methods of treating apol-1 dependent focal segmental glomerulosclerosis
IL296423A (en) 2020-04-22 2022-11-01 Anima Biotech Inc Collagen 1 translation inhibitors and methods of use thereof
WO2021220178A1 (en) 2020-04-29 2021-11-04 Cominnex Zrt. Iap antagonists and their therapeutic applications
JP2023524563A (ja) 2020-05-07 2023-06-12 ラムバム メド-テック リミテッド Apol1-関連疾患の治療に使用するための組成物
CN115867543A (zh) 2020-06-12 2023-03-28 弗特克斯药品有限公司 Apol1抑制剂的固体形式及其使用方法
CA3185604A1 (en) 2020-06-12 2021-12-16 Vertex Pharmaceuticals Incorporated Inhibitors of apol1 and use of the same
CN115867532A (zh) 2020-06-12 2023-03-28 弗特克斯药品有限公司 Apol1的抑制剂及其用途
CN115996923B (zh) 2020-08-26 2025-07-18 海思科医药集团股份有限公司 一种作为二肽基肽酶1抑制剂的腈衍生物及其用途
CN116547287B (zh) 2020-08-26 2025-09-26 弗特克斯药品有限公司 Apol1的抑制剂及其使用方法
US20230119114A1 (en) 2021-08-26 2023-04-20 Vertex Pharmaceuticals Incorporated Solid forms of apol1 inhibitors and methods of using same
EP4440697A1 (en) 2021-11-30 2024-10-09 Vertex Pharmaceuticals Incorporated Spirocyclic inhibitors of apol1 and methods of using same
US12612379B2 (en) 2021-11-30 2026-04-28 Vertex Pharmaceuticals Incorporated Inhibitors of APOL1 and methods of using same
AU2023219516A1 (en) 2022-02-08 2024-08-22 Vertex Pharmaceuticals Incorporated 2-methyl-4-phenylpiperidin-4-ol derivatives as inhibitors of apol1 and methods of using same
CA3251050A1 (en) 2022-02-08 2023-08-17 Vertex Pharmaceuticals Incorporated 2-METHYL-4',5'-DIHYDROSPIRO[PIPERIDINE-4,7'-THIENO[2,3-C]PYRAN] DERIVATIVES USED AS APOL1 INHIBITORS AND THEIR METHODS OF USE
EP4476228A1 (en) 2022-02-08 2024-12-18 Vertex Pharmaceuticals Incorporated 4',5'-dihydrospiro[piperidine-4,7'-thieno[2,3-c]pyran] derivatives as inhibitors of apol1 and methods of using same
CN119212986A (zh) 2022-02-08 2024-12-27 弗特克斯药品有限公司 作为apol1的抑制剂的螺哌啶衍生物及其使用方法

Similar Documents

Publication Publication Date Title
JP2023539194A5 (https=)
JP2024544060A5 (https=)
RU2326869C2 (ru) Производные пиридазин-3(2h)-она в качестве ингибиторов фосфодиэстеразы 4 (pde4), способ их получения, фармацевтическая композиция и способ лечения
KR890000020B1 (ko) 아릴옥시-및 아릴티오-하이드록시프로필-피페라지닐 아세트아닐리드 및 그의 제조방법
KR101086678B1 (ko) 4-[[4-[[4-(2-시아노에테닐)-2,6-디메틸페닐]아미노]-2-피리미디닐]아미노]벤조니트릴의 제조방법
JP2025505644A5 (https=)
IL300298B2 (en) Inhibitors of apol1 and methods of using same
RU2005136368A (ru) Производные пиперазина и их применение для лечения неврологических и психиатрических заболеваний
JP2024543934A5 (https=)
JP2025505200A5 (https=)
RU2007141892A (ru) 5-метил-1-(замещенный фенил)-2-(1н)-пиридон для производства медикаментов для лечения фиброза в органах и тканях
JP2005533024A5 (https=)
JP2020517677A5 (https=)
JP2025505647A5 (https=)
EA010017B1 (ru) Замещённые арилтиомочевины, применимые в качестве ингибиторов репликации вирусов
CA2405408A1 (en) Pyrazole compounds
JP2015524483A5 (https=)
JP7285027B2 (ja) 化合物、その薬学的に許容される塩又は立体異性体、その使用、及び薬物組成物
US20030087936A1 (en) Imidazolidinone compounds
AU2001246577B2 (en) Pyridazinyl phenyl hydrazones useful against congestive heart failure
JP2023551435A (ja) B型肝炎ウイルス感染症の処置及び予防のためのn置換4-(1,3-アリールオキサゾロ-2-イル)フェニル化合物
JPS6287574A (ja) 新規なn置換3,4−ジヒドロピリミジン−2−オン誘導体、その製造法及び循環器系疾患治療剤
EP4038065A1 (en) Substituted pyrimidine for the treatment and prophylaxis of hepatitis b virus infection
JP2022517984A (ja) 環内チアミジノアミド-アリールアミド系化合物及びb型肝炎を治療するためのその使用
RU2275369C2 (ru) Модуляторы натриевых каналов, являющиеся производными 2-пиперидилимидазолов